The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Abstract In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who p...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/480280eb7ab4458fa7a0a13c1dcceb2c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:480280eb7ab4458fa7a0a13c1dcceb2c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:480280eb7ab4458fa7a0a13c1dcceb2c2021-12-02T18:18:58ZThe prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial10.1038/s41598-021-92774-z2045-2322https://doaj.org/article/480280eb7ab4458fa7a0a13c1dcceb2c2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92774-zhttps://doaj.org/toc/2045-2322Abstract In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian cancer centers were retrospectively collected and analyzed. From 2003 to 2017, 491 HER2‐positive mBC patients were included. Of these, 102 (20.7%) had been initially diagnosed as HER2-negative early BC. Estrogen and/or progesterone receptor were more expressed in patients with HER2-discordance compared to patients with HER2-concordant status (p < 0.0001 and p = 0.006, respectively). HER2-discordant tumors were characterized also by a lower rate of brain metastases (p = 0.01) and a longer disease free interval (p < 0.0001). Median overall survival was longer, although not statistically significant, in the subgroup of patients with HER2-discordant cancer with respect to patients with HER2-concordant status (140 vs 78 months, p = 0.07). Our findings suggest that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2-concordant patients.Laura PizzutiMaddalena BarbaMarco MazzottaEriseld KrasniqiMarcello Maugeri-SaccàTeresa GamucciRossana BerardiLorenzo LiviCorrado FicorellaClara NatoliEnrico CortesiDaniele GeneraliNicla La VerdeAlessandra CassanoEmilio BriaLuca MoscettiAndrea MichelottiVincenzo AdamoClaudio ZamagniGiuseppe ToniniDomenico SergiDaniele MarinelliGiancarlo PaolettiSilverio TomaoAndrea BotticelliPaolo MarchettiNicola TinariAntonino GrassadoniaMaria Rosaria ValerioRosanna MirabelliMaria Agnese FabbriNicola D’OstilioEnzo VeltriDomenico CorsiOrnella GarroneIda ParisGiuseppina SarobbaIcro MeattiniMirco PistelliFrancesco GiottaVito LorussoCarlo GarufiAntonio RussoMarina CazzanigaPietro Del MedicoMario RoselliAngela VaccaroLetizia PerracchioAnna di BenedettoTheodora DaraliotiIsabella SperdutiRuggero De MariaAngelo Di LeoGiuseppe SanguinetiGennaro CilibertoPatrizia ViciNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Laura Pizzuti Maddalena Barba Marco Mazzotta Eriseld Krasniqi Marcello Maugeri-Saccà Teresa Gamucci Rossana Berardi Lorenzo Livi Corrado Ficorella Clara Natoli Enrico Cortesi Daniele Generali Nicla La Verde Alessandra Cassano Emilio Bria Luca Moscetti Andrea Michelotti Vincenzo Adamo Claudio Zamagni Giuseppe Tonini Domenico Sergi Daniele Marinelli Giancarlo Paoletti Silverio Tomao Andrea Botticelli Paolo Marchetti Nicola Tinari Antonino Grassadonia Maria Rosaria Valerio Rosanna Mirabelli Maria Agnese Fabbri Nicola D’Ostilio Enzo Veltri Domenico Corsi Ornella Garrone Ida Paris Giuseppina Sarobba Icro Meattini Mirco Pistelli Francesco Giotta Vito Lorusso Carlo Garufi Antonio Russo Marina Cazzaniga Pietro Del Medico Mario Roselli Angela Vaccaro Letizia Perracchio Anna di Benedetto Theodora Daralioti Isabella Sperduti Ruggero De Maria Angelo Di Leo Giuseppe Sanguineti Gennaro Ciliberto Patrizia Vici The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial |
| description |
Abstract In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian cancer centers were retrospectively collected and analyzed. From 2003 to 2017, 491 HER2‐positive mBC patients were included. Of these, 102 (20.7%) had been initially diagnosed as HER2-negative early BC. Estrogen and/or progesterone receptor were more expressed in patients with HER2-discordance compared to patients with HER2-concordant status (p < 0.0001 and p = 0.006, respectively). HER2-discordant tumors were characterized also by a lower rate of brain metastases (p = 0.01) and a longer disease free interval (p < 0.0001). Median overall survival was longer, although not statistically significant, in the subgroup of patients with HER2-discordant cancer with respect to patients with HER2-concordant status (140 vs 78 months, p = 0.07). Our findings suggest that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2-concordant patients. |
| format |
article |
| author |
Laura Pizzuti Maddalena Barba Marco Mazzotta Eriseld Krasniqi Marcello Maugeri-Saccà Teresa Gamucci Rossana Berardi Lorenzo Livi Corrado Ficorella Clara Natoli Enrico Cortesi Daniele Generali Nicla La Verde Alessandra Cassano Emilio Bria Luca Moscetti Andrea Michelotti Vincenzo Adamo Claudio Zamagni Giuseppe Tonini Domenico Sergi Daniele Marinelli Giancarlo Paoletti Silverio Tomao Andrea Botticelli Paolo Marchetti Nicola Tinari Antonino Grassadonia Maria Rosaria Valerio Rosanna Mirabelli Maria Agnese Fabbri Nicola D’Ostilio Enzo Veltri Domenico Corsi Ornella Garrone Ida Paris Giuseppina Sarobba Icro Meattini Mirco Pistelli Francesco Giotta Vito Lorusso Carlo Garufi Antonio Russo Marina Cazzaniga Pietro Del Medico Mario Roselli Angela Vaccaro Letizia Perracchio Anna di Benedetto Theodora Daralioti Isabella Sperduti Ruggero De Maria Angelo Di Leo Giuseppe Sanguineti Gennaro Ciliberto Patrizia Vici |
| author_facet |
Laura Pizzuti Maddalena Barba Marco Mazzotta Eriseld Krasniqi Marcello Maugeri-Saccà Teresa Gamucci Rossana Berardi Lorenzo Livi Corrado Ficorella Clara Natoli Enrico Cortesi Daniele Generali Nicla La Verde Alessandra Cassano Emilio Bria Luca Moscetti Andrea Michelotti Vincenzo Adamo Claudio Zamagni Giuseppe Tonini Domenico Sergi Daniele Marinelli Giancarlo Paoletti Silverio Tomao Andrea Botticelli Paolo Marchetti Nicola Tinari Antonino Grassadonia Maria Rosaria Valerio Rosanna Mirabelli Maria Agnese Fabbri Nicola D’Ostilio Enzo Veltri Domenico Corsi Ornella Garrone Ida Paris Giuseppina Sarobba Icro Meattini Mirco Pistelli Francesco Giotta Vito Lorusso Carlo Garufi Antonio Russo Marina Cazzaniga Pietro Del Medico Mario Roselli Angela Vaccaro Letizia Perracchio Anna di Benedetto Theodora Daralioti Isabella Sperduti Ruggero De Maria Angelo Di Leo Giuseppe Sanguineti Gennaro Ciliberto Patrizia Vici |
| author_sort |
Laura Pizzuti |
| title |
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial |
| title_short |
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial |
| title_full |
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial |
| title_fullStr |
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial |
| title_full_unstemmed |
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial |
| title_sort |
prognostic relevance of her2-positivity gain in metastatic breast cancer in the changeher trial |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/480280eb7ab4458fa7a0a13c1dcceb2c |
| work_keys_str_mv |
AT laurapizzuti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT maddalenabarba theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marcomazzotta theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT eriseldkrasniqi theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marcellomaugerisacca theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT teresagamucci theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT rossanaberardi theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT lorenzolivi theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT corradoficorella theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT claranatoli theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT enricocortesi theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT danielegenerali theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT niclalaverde theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT alessandracassano theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT emiliobria theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT lucamoscetti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT andreamichelotti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT vincenzoadamo theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT claudiozamagni theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giuseppetonini theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT domenicosergi theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT danielemarinelli theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giancarlopaoletti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT silveriotomao theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT andreabotticelli theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT paolomarchetti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT nicolatinari theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT antoninograssadonia theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT mariarosariavalerio theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT rosannamirabelli theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT mariaagnesefabbri theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT nicoladostilio theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT enzoveltri theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT domenicocorsi theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT ornellagarrone theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT idaparis theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giuseppinasarobba theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT icromeattini theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT mircopistelli theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT francescogiotta theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT vitolorusso theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT carlogarufi theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT antoniorusso theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marinacazzaniga theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT pietrodelmedico theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marioroselli theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT angelavaccaro theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT letiziaperracchio theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT annadibenedetto theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT theodoradaralioti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT isabellasperduti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT ruggerodemaria theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT angelodileo theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giuseppesanguineti theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT gennarociliberto theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT patriziavici theprognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT laurapizzuti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT maddalenabarba prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marcomazzotta prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT eriseldkrasniqi prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marcellomaugerisacca prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT teresagamucci prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT rossanaberardi prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT lorenzolivi prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT corradoficorella prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT claranatoli prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT enricocortesi prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT danielegenerali prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT niclalaverde prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT alessandracassano prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT emiliobria prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT lucamoscetti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT andreamichelotti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT vincenzoadamo prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT claudiozamagni prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giuseppetonini prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT domenicosergi prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT danielemarinelli prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giancarlopaoletti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT silveriotomao prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT andreabotticelli prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT paolomarchetti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT nicolatinari prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT antoninograssadonia prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT mariarosariavalerio prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT rosannamirabelli prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT mariaagnesefabbri prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT nicoladostilio prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT enzoveltri prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT domenicocorsi prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT ornellagarrone prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT idaparis prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giuseppinasarobba prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT icromeattini prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT mircopistelli prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT francescogiotta prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT vitolorusso prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT carlogarufi prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT antoniorusso prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marinacazzaniga prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT pietrodelmedico prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT marioroselli prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT angelavaccaro prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT letiziaperracchio prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT annadibenedetto prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT theodoradaralioti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT isabellasperduti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT ruggerodemaria prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT angelodileo prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT giuseppesanguineti prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT gennarociliberto prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial AT patriziavici prognosticrelevanceofher2positivitygaininmetastaticbreastcancerinthechangehertrial |
| _version_ |
1718378152963604480 |